The epidemiology of hepatitis C virus in Iran

Systematic review and meta-analyses

Sarwat Mahmud, Vajiheh Akbarzadeh, Laith Aburaddad

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures. Our meta-analyses estimated HCV prevalence at 0.3% among the general population, 6.2% among intermediate risk populations, 32.1% among high risk populations, and 4.6% among special clinical populations. Our meta-analyses for subpopulations estimated HCV prevalence at 52.2% among people who inject drugs (PWID), 20.0% among populations at high risk of healthcare-related exposures, and 7.5% among populations with liver-related conditions. Genotype 1 was the most frequent circulating strain at 58.2%, followed by genotype 3 at 39.0%. HCV prevalence in the general population was lower than that found in other Middle East and North Africa countries and globally. However, HCV prevalence was high in PWID and populations at high risk of healthcare-related exposures. Ongoing transmission appears to be driven by drug injection and specific healthcare procedures.

Original languageEnglish
Article number150
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Iran
Hepacivirus
Meta-Analysis
Epidemiology
Population
Delivery of Health Care
Genotype
Pharmaceutical Preparations
Northern Africa
Eastern Africa
Hepatitis C Antibodies
Middle East
Incidence
Guidelines
Injections
Liver

ASJC Scopus subject areas

  • General

Cite this

The epidemiology of hepatitis C virus in Iran : Systematic review and meta-analyses. / Mahmud, Sarwat; Akbarzadeh, Vajiheh; Aburaddad, Laith.

In: Scientific Reports, Vol. 8, No. 1, 150, 01.12.2018.

Research output: Contribution to journalArticle

@article{4be3423642cf48bcb997a44dcb912d4b,
title = "The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses",
abstract = "The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures. Our meta-analyses estimated HCV prevalence at 0.3{\%} among the general population, 6.2{\%} among intermediate risk populations, 32.1{\%} among high risk populations, and 4.6{\%} among special clinical populations. Our meta-analyses for subpopulations estimated HCV prevalence at 52.2{\%} among people who inject drugs (PWID), 20.0{\%} among populations at high risk of healthcare-related exposures, and 7.5{\%} among populations with liver-related conditions. Genotype 1 was the most frequent circulating strain at 58.2{\%}, followed by genotype 3 at 39.0{\%}. HCV prevalence in the general population was lower than that found in other Middle East and North Africa countries and globally. However, HCV prevalence was high in PWID and populations at high risk of healthcare-related exposures. Ongoing transmission appears to be driven by drug injection and specific healthcare procedures.",
author = "Sarwat Mahmud and Vajiheh Akbarzadeh and Laith Aburaddad",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-017-18296-9",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The epidemiology of hepatitis C virus in Iran

T2 - Systematic review and meta-analyses

AU - Mahmud, Sarwat

AU - Akbarzadeh, Vajiheh

AU - Aburaddad, Laith

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures. Our meta-analyses estimated HCV prevalence at 0.3% among the general population, 6.2% among intermediate risk populations, 32.1% among high risk populations, and 4.6% among special clinical populations. Our meta-analyses for subpopulations estimated HCV prevalence at 52.2% among people who inject drugs (PWID), 20.0% among populations at high risk of healthcare-related exposures, and 7.5% among populations with liver-related conditions. Genotype 1 was the most frequent circulating strain at 58.2%, followed by genotype 3 at 39.0%. HCV prevalence in the general population was lower than that found in other Middle East and North Africa countries and globally. However, HCV prevalence was high in PWID and populations at high risk of healthcare-related exposures. Ongoing transmission appears to be driven by drug injection and specific healthcare procedures.

AB - The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures. Our meta-analyses estimated HCV prevalence at 0.3% among the general population, 6.2% among intermediate risk populations, 32.1% among high risk populations, and 4.6% among special clinical populations. Our meta-analyses for subpopulations estimated HCV prevalence at 52.2% among people who inject drugs (PWID), 20.0% among populations at high risk of healthcare-related exposures, and 7.5% among populations with liver-related conditions. Genotype 1 was the most frequent circulating strain at 58.2%, followed by genotype 3 at 39.0%. HCV prevalence in the general population was lower than that found in other Middle East and North Africa countries and globally. However, HCV prevalence was high in PWID and populations at high risk of healthcare-related exposures. Ongoing transmission appears to be driven by drug injection and specific healthcare procedures.

UR - http://www.scopus.com/inward/record.url?scp=85040458567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040458567&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-18296-9

DO - 10.1038/s41598-017-18296-9

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 150

ER -